Related Experiment Video

Updated: Jun 23, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Multidrug resistance proteins in renal cell carcinoma

I Hodorová1, S Rybárová, P Solár

  • 1Department of Anatomy, Faculty of Medicine, P. J. Safárik University in Kosice, Kosice, Slovak Republic. ingrid.hodorova@post.sk

Folia Biologica
|April 28, 2009
PubMed

Insights

Multidrug resistance (MDR) proteins like MDR1, MRP1, and LRP are frequently expressed in renal cell carcinoma, impacting treatment response. Their expression correlates with nuclear grade, suggesting a role in cancer progression and chemotherapy resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Chemotherapy resistance is a significant challenge in treating renal cancer, with mechanisms often poorly understood.
  • Multidrug resistance (MDR) is a primary cause of treatment failure, mediated by MDR proteins.
  • These proteins, including ABC transporters (e.g., MDR1/Pgp) and non-ABC transporters (e.g., LRP), facilitate drug efflux from cancer cells.

Purpose of the Study:

  • To investigate the expression levels of MDR1/Pgp, MRP1, and LRP in renal cell carcinoma (RCC) samples.
  • To analyze the correlation between MDR protein expression and clinicopathological parameters, particularly nuclear grade.

Main Methods:

  • Immunohistochemical assay was employed to detect MDR1/Pgp, MRP1, and LRP expression.
  • The study analyzed 47 renal cell carcinoma specimens.
  • Results were correlated with nuclear grade and other clinical and pathological factors.

Main Results:

  • A high prevalence of MDR protein expression was observed in RCC specimens.
  • Specifically, 21% showed MDR1 positivity, 62% showed MRP1 positivity, and 76.6% showed LRP positivity.
  • Significant associations were found between MDR1 and LRP expression and nuclear grade, but not between MRP1 and nuclear grade or other clinical parameters.

Conclusions:

  • MDR proteins are widely expressed in renal cell carcinoma.
  • The expression of MDR1 and LRP is significantly associated with nuclear grade, suggesting a potential role in RCC aggressiveness.
  • Further research is warranted to elucidate the precise mechanisms of MDR in renal cancer and its impact on treatment efficacy.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...